Abstract
Background: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is characterized by intraductal papillary proliferation of mucin-producing epithelial cells that exhibit various degrees of dysplasia. IPMN is classified as the main duct type (MD-IPMN) and the branch duct type (BD-IPMN) according to the location of involvement, and into four histological subtypes (gastric, intestinal, pancreatobiliary, and oncocytic) according to the histomorphological and immunohistochemical characteristics. Mucin core protein expression correlates with the biological behavior and prognosis of the tumor. DNA analysis has shown that IPMN is associated with a number of gene mutations, but the roles of many of these mutations require further investigation. Most patients with MD-IPMN undergo tumor resection. Patients with BD-IPMN who do not undergo resection may develop malignant change, and concomitant separate pancreatic cancer occurs in 2-10% of patients with IPMN. Patients with a strong family history may develop multiple BD-IPMNs as well as concomitant pancreatic cancer. Malignant changes are relatively easy to detect, especially by endoscopic ultrasonography (EUS), but the optimal surveillance protocol is currently unclear. Key Messages: The 2012 guidelines for the management ofIPMN recommend that patients with ‘high-risk stigmata' (obstructive jaundice, enhanced solid component, and main pancreatic duct size ≥10 mm) should undergo resection. Patients with ‘worrisome features' (cyst size ≥3 cm, thickened enhanced cyst walls, non-enhanced mural nodules, main pancreatic duct size 5-9 mm, abrupt change in main pancreatic duct caliber with distal pancreatic atrophy, lymphadenopathy, and clinical acute pancreatitis) should be evaluated by EUS. EUS is a more sensitive test than computed tomography or magnetic resonance imaging for the early detection of malignancy. Conclusions: Most patients with MD-IPMN should undergo tumor resection. Patients with BD-IPMN who do not undergo resection should undergo careful surveillance including EUS for the early detection of malignant change and separate pancreatic cancer.
Journal Section:
Invited Review
References
1.
Ohashi K, Tajiri H, Gondo M, Yokoyama Y, Maruyama M, Takekoshi T, Matsuura Y, Kasumi F, Takagi K, Kato Y: A case of cystadenocarcinoma of the pancreas forming bilio-pancreatic fistula. Prog Dig Endosc 1980;17:261-264.
2.
Ohhashi K, Murakami F, Maruyama M, Takekoshi T, Ohta H, Ohhashi I, Takagi K, Kato Y: Four cases of mucous secreting pancreatic cancer. Prog Dig Endosc 1982;20:348-351.
3.
Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, Yamaguchi K, Yamao K, Matsuno S; International Association of Pancreatology: International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17-32.
[PubMed]
4.
Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, Kimura W, Levy P, Pitman MB, Schmidt CM, Shimizu M, Wolfgang CL, Yamaguchi K, Yamao K; International Association of Pancreatology: International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology 2012;12:183-197.
[PubMed]
5.
Tanaka M: Intraductal Papillary Mucinous Neoplasm, ed 1. Tokyo, Springer, 2014.
6.
Adsay NV, Fukushima N, Furukawa T, Hruban RH, Klimstra DS, Kloppel G, Offerhaus GJA, Pitman MB, Shimizu M, Zamboni G: Intraductal neoplasm of the pancreas; in Bosman FT, Carneiro F, Hruban RH, Theise ND (eds): WHO classification of tumors of digestive system. Lyon, WHO Press, 2010, pp 304-313.
7.
Sessa F, Solcia E, Capella C, Bonato M, Scarpa A, Zamboni G, Pellegata NS, Ranzani GN, Rickaert F, Klöppel G: Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch 1994;425:357-367.
[PubMed]
8.
Tamura K, Ohtsuka T, Ideno N, Aso T, Shindo K, Aishima S, Ohuchida K, Takahata S, Ushijima Y, Ito T, Oda Y, Mizumoto K, Tanaka M: Treatment strategy for main duct intraductal papillary mucinous neoplasms of the pancreas based on the assessment of recurrence in the remnant pancreas after resection: a retrospective review. Ann Surg 2014;259:360-368.
[PubMed]
9.
Ohtsuka T, Matsunaga T, Kimura H, Watanabe Y, Tamura K, Ideno N, Aso T, Miyasaka Y, Ueda J, Takahata S, Osoegawa T, Igarashi H, Ito T, Ushijima Y, Ookubo F, Oda Y, Mizumoto K, Tanaka M: Role of pancreatic juice cytology in the preoperative management of intraductal papillary mucinous neoplasm of the pancreas in the era of international consensus guidelines 2012. World J Surg 2014;38:2994-3001.
[PubMed]
10.
Ito Y, Blackstone MO, Frank PH, Skinner DB: Mucinous biliary obstruction associated with a cystic adenocarcinoma of the pancreas. Gastroenterology 1977;73:1410-1412.
[PubMed]
11.
Conley CR, Scheithauer BW, Weiland LH, van Heerden JA: Diffuse intraductal papillary adenocarcinoma of the pancreas. Ann Surg 1987;205:246-249.
[PubMed]
12.
Rogers PN, Seywright MM, Murray WR: Diffuse villous adenoma of the pancreatic duct. Pancreas 1987;2:727-730.
[PubMed]
13.
Payan MJ, Xerri L, Moncada K, Bastid C, Agostini S, Sastre B, Sahel J, Choux R: Villous adenoma of the main pancreatic duct: a potentially malignant tumor? Am J Gastroenterol 1990;85:459-463.
[PubMed]
14.
Agostini S, Choux R, Payan MJ, Sastre B, Sahel J, Clement JP: Mucinous pancreatic duct ectasia in the body of the pancreas. Radiology 1989;170:815-816.
[PubMed]
15.
Köhler B, Köhler G, Riemann J: Pancreoscopic diagnosis of intraductal cystadenoma of the pancreas. Dig Dis Sci 1990;35:382-384.
[PubMed]
16.
Rickaert F, Cremer M, Deveire J, Tavares L, Lambilliotte JP, Schröder S, Wurbs D, Klöppel G: Intraductal mucin-hypersecreting neoplasms of the pancreas. A clinicopathologic study of eight patients. Gastroenterology 1991;101:512-519.
[PubMed]
17.
Bastid C, Bernard JP, Sarles H, Payan MJ, Sahel J: Mucinous ductal ectasia of the pancreas: a premalignant disease and a cause of obstructive pancreatitis. Pancreas 1991;6:15-22.
[PubMed]
18.
Obara T, Saitoh Y, Maguchi H, Ura H, Yokota K, Okamura K, Namiki M: Papillary adenoma of the pancreas with excessive mucin secretion. Pancreas 1992;7:114-117.
[PubMed]
19.
Kawarada Y, Yano T, Yamamoto T, Yokoi H, Imai T, Ogura Y, Mizumoto R: Intraductal mucin-producing tumors of the pancreas. Am J Gastroenterol 1992;87:634-638.
[PubMed]
20.
Yamada M, Kozuka S, Yamao K, Nakazawa S, Naitoh Y, Tsukamoto Y: Mucin-producing tumor of the pancreas. Cancer 1991;68:159-168.
[PubMed]
21.
Furuta K, Watanabe H, Ikeda S: Differences between solid and duct-ectatic types of pancreatic ductal carcinomas. Cancer 1992;69:1327-1333.
[PubMed]
22.
Yamaguchi K, Tanaka M: Mucin-hypersecreting tumor of the pancreas with mucin extrusion through an enlarged papilla. Am J Gastroenterol 1991;86:835-839.
[PubMed]
23.
Furukawa T, Takahashi T, Kobari M, Matsuno S: The mucus-hypersecreting tumor of the pancreas. Development and extension visualized by three-dimensional computerized mapping. Cancer 1992;70:1505-1513.
[PubMed]
24.
Yamaguchi K, Chijiiwa K, Shimizu S, Yokohata K, et al: Intraductal papillary neoplasm of the pancreas: a clinical review of 13 benign and four malignant tumours. Eur J Surg 1999;165:223-229.
[PubMed]
25.
Klöppel G, Solcia E, Longnecker DS, Capella C, Sobin LH; World Health Organization: International histological classification of tumours. Histological typing of tumours of the exocrine pancreas, ed 2. Berlin, Springer-Verlag, 1996, pp 1-61.
26.
Solcia E, Capella C, Klöppel G: Tumors of the pancreas; in Rosai J, Sorbin L (eds): Atlas of Tumor Pathology, fascicle 20, 3rd series. Washington, DC, Armed Forces Institute of Pathology, 1997, pp 1-262.
27.
Loftus EV Jr, Olivares-Pakzad BA, Batts KP, Adkins MC, Stephens DH, Sarr MG, DiMagno EP: Intraductal papillary-mucinous tumors of the pancreas: clinicopathologic features, outcome, and nomenclature. Gastroenterology 1996;110:1909-1918.
[PubMed]
28.
Osako M, Yonezawa S, Siddiki B, Huang J, Ho JJ, Kim YS, Sato E: Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors. Cancer 1993;71:2191-2199.
[PubMed]
29.
Nakamura A, Horinouchi M, Goto M, Nagata K, Sakoda K, Takao S, Imai K, Kim YS, Sato E, Yonezawa S: New classification of pancreatic intraductal papillary-mucinous tumour by mucin expression: its relationship with potential for malignancy. J Pathol 2002;197:201-210.
[PubMed]
30.
Furukawa T, Klöppel G, Volkan Adsay N, Albores-Saavedra J, Fukushima N, Horii A, Hruban RH, Kato Y, Klimstra DS, Longnecker DS, Lüttges J, Offerhaus GJ, Shimizu M, Sunamura M, Suriawinata A, Takaori K, Yonezawa S: Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 2005;447:794-799.
[PubMed]
31.
Sadakari Y, Ohuchida K, Nakata K, Ohtsuka T, Aishima S, Takahata S, Nakamura M, Mizumoto K, Tanaka M: Invasive carcinoma derived from the nonintestinal type intraductal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from the intestinal type. Surgery 2010;147:812-817.
[PubMed]
32.
Furukawa T, Hatori T, Fujita I, Yamamoto M, Kobayashi M, Ohike N, Morohoshi T, Egawa S, Unno M, Takao S, Osako M, Yonezawa S, Mino-Kenudson M, Lauwers GY, Yamaguchi H, Ban S, Shimizu M: Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut 2011;60:509-516.
[PubMed]
33.
Nakata K, Ohuchida K, Aishima S, Sadakari Y, Kayashima T, Miyasaka Y, Nagai E, Mizumoto K, Tanaka M, Tsuneyoshi M, Oda Y: Invasive carcinoma derived from intestinal-type intraductal papillary mucinous neoplasm is associated with minimal invasion, colloid carcinoma, and less invasive behavior, leading to a better prognosis. Pancreas 2011;40:581-587.
[PubMed]
34.
Mino-Kenudson M, Fernández-del Castillo C, Baba Y, Valsangkar NP, Liss AS, Hsu M, Correa-Gallego C, Ingkakul T, Perez Johnston R, Turner BG, Androutsopoulos V, Deshpande V, McGrath D, Sahani DV, Brugge WR, Ogino S, Pitman MB, Warshaw AL, Thayer SP: Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 2011;60:1712-1720.
[PubMed]
35.
Ohno E, Hirooka Y, Itoh A, Ishigami M, Katano Y, Ohmiya N, Niwa Y, Goto H: Intraductal papillary mucinous neoplasms of the pancreas: differentiation of malignant and benign tumors by endoscopic ultrasound findings of mural nodules. Ann Surg 2009;249:628-634.
[PubMed]
36.
Nishihara K, Fukuda T, Tsuneyoshi M, Kominami T, Maeda S, Saku M: Intraductal papillary neoplasm of the pancreas. Cancer 1993;72:689-696.
[PubMed]
37.
Fléjou JF, Boulange B, Bernades P, Belghiti J, Hénin D: p53 protein expression and DNA ploidy in cystic tumors of the pancreas. Pancreas 1996;13:247-252.
[PubMed]
38.
Yanagisawa A, Kato Y, Ohtake K, Kitagawa T, Ohashi K, Hori M, Takagi K, Sugano H: c-Ki-ras point mutations in ductectatic-type mucinous cystic neoplasms of the pancreas. Jpn J Cancer Res 1991;82:1057-1060.
[PubMed]
39.
Tada M, Omata M, Ohto M: Ras gene mutations in intraductal papillary neoplasms of the pancreas. Analysis in five cases. Cancer 1991;67:634-637.
[PubMed]
40.
Lemoine NR, Jain S, Hughes CM, Staddon SL, Maillet B, Hall PA, Klöppel G: Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 1992;102:230-236.
[PubMed]
41.
Satoh K, Sawai T, Shimosegawa T, Koizumi M, Yamazaki T, Mochizuki F, Toyota T: The point mutation of c-Ki-ras at codon 12 in carcinoma of the pancreatic head region and in intraductal mucin-hypersecreting neoplasm of the pancreas. Int J Pancreatol 1993;14:135-143.
[PubMed]
42.
Kondo H, Sugano K, Fukayama N, Hosokawa K, Ohkura H, Ohtsu A, Mukai K, Yoshida S: Detection of K-ras gene mutations at codon 12 in the pancreatic juice of patients with intraductal papillary mucinous tumors of the pancreas. Cancer 1997;79:900-905.
[PubMed]
43.
Hong SM, Vincent A, Kanda M, Leclerc J, Omura N, Borges M, Klein AP, Canto MI, Hruban RH, Goggins M: Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer. Clin Cancer Res 2012;18:4303-4312.
[PubMed]
44.
Wu J, Matthaei H, Maitra A, Dal Molin M, Wood LD, Eshleman JR, Goggins M, Canto MI, Schulick RD, Edil BH, Wolfgang CL, Klein AP, Diaz LA Jr, Allen PJ, Schmidt CM, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B: Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med 2011;3:92ra66.
[PubMed]
45.
Dal Molin M, Matthaei H, Wu J, Blackford A, Debeljak M, Rezaee N, Wolfgang CL, Butturini G, Salvia R, Bassi C, Goggins MG, Kinzler KW, Vogelstein B, Eshleman JR, Hruban RH, Maitra A: Clinicopathological correlates of activating GNAS mutations in intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Ann Surg Oncol 2013;20:3802-3808.
[PubMed]
46.
Schönleben F, Qiu W, Bruckman KC, Ciau NT, Li X, Lauerman MH, Frucht H, Chabot JA, Allendorf JD, Remotti HE, Su GH: BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett 2007;249:242-248.
[PubMed]
47.
Furukawa T, Kuboki Y, Tanji E, Yoshida S, Hatori T, Yamamoto M, Shibata N, Shimizu K, Kamatani N, Shiratori K: Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 2011;1:161.
[PubMed]
48.
Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, Eshleman JR, Goggins MG, Wolfgang CL, Canto MI, Schulick RD, Edil BH, Choti MA, Adsay V, Klimstra DS, Offerhaus GJ, Klein AP, Kopelovich L, Carter H, Karchin R, Allen PJ, Schmidt CM, Naito Y, Diaz LA Jr, Kinzler KW, Papadopoulos N, Hruban RH, Vogelstein B: Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A 2011;108:21188-21193.
[PubMed]
49.
Amato E, Molin MD, Mafficini A, Yu J, Malleo G, Rusev B, Fassan M, Antonello D, Sadakari Y, Castelli P, Zamboni G, Maitra A, Salvia R, Hruban RH, Bassi C, Capelli P, Lawlor RT, Goggins M, Scarpa A: Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 2014;233:217-227.
[PubMed]
50.
Tanaka M, Yokohata K, Konomi H, Yamaguchi K, Chijiiwa K, Ohta M: Segmental balloon cytology for preoperative localization of in situ pancreatic cancer. Gastrointest Endosc 1997;46:447-449.
[PubMed]
51.
Yamaguchi K, Nakamura K, Yokohata K, Shimizu S, Chijiiwa K, Tanaka M: Pancreatic cyst as a sentinel of in situ carcinoma of the pancreas. Report of two cases. Int J Pancreatol 1997;22:227-231.
[PubMed]
52.
Yamaguchi K, Ohuchida J, Ohtsuka T, Nakano K, Tanaka M: Intraductal papillary-mucinous tumor of the pancreas concomitant with ductal carcinoma of the pancreas. Pancreatology 2002;2:484-490.
[PubMed]
53.
Kuroki T, Tajima Y, Tsuneoka N, Adachi T, Kanematsu T: Combined pancreatic resection and pancreatic duct-navigation surgery for multiple lesions of the pancreas: intraductal papillary mucinous neoplasm of the pancreas concomitant with ductal carcinoma of the pancreas. Hepatogastroenterology 2008;55:1830-1833
[PubMed]
54.
Jarry J, Belleannee G, Rault A, Sa Cunha A, Collet D: Can an intraductal papillary mucinous tumor be a potential indicator of concurrent adenocarcinoma of the pancreas? JOP 2010;11:55-57.
[PubMed]
55.
Tada M, Kawabe T, Arizumi M, Togawa O, Matsubara S, Yamamoto N, Nakai Y, Sasahira N, Hirano K, Tsujino T, Tateishi K, Isayama H, Toda N, Yoshida H, Omata M: Pancreatic cancer in patients with pancreatic cystic lesions: a prospective study in 197 patients. Clin Gastroenterol Hepatol 2006;4:1265-1270.
[PubMed]
56.
Uehara H, Nakaizumi A, Ishikawa O, Iishi H, Tatsumi K, Takakura R, Ishida T, Takano Y, Tanaka S, Takenaka A: Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas. Gut 2008;57:1561-1565.
[PubMed]
57.
Ingkakul T, Sadakari Y, Ienaga J, Satoh N, Takahata S, Tanaka M: Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas. Ann Surg 2010;251:70-75.
[PubMed]
58.
Tanno S, Nakano Y, Koizumi K, Sugiyama Y, Nakamura K, Sasajima J, Nishikawa T, Mizukami Y, Yanagawa N, Fujii T, Okumura T, Obara T, Kohgo Y: Pancreatic ductal adenocarcinomas in long-term follow-up patients with branch duct intraductal papillary mucinous neoplasms. Pancreas 2010;39:36-40.
[PubMed]
59.
Tanno S, Nakano Y, Sugiyama Y, Nakamura K, Sasajima J, Koizumi K, Yamazaki M, Nishikawa T, Mizukami Y, Yanagawa N, Fujii T, Obara T, Okumura T, Kohgo Y: Incidence of synchronous and metachronous pancreatic carcinoma in 168 patients with branch duct intraductal papillary mucinous neoplasm. Pancreatology 2010;10:173-178.
[PubMed]
60.
Ikeuchi N, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Kurihara T, Ishii K, Tsuji S, Umeda J, Moriyasu F, Tsuchida A, Kasuya K: Prognosis of cancer with branch duct type IPMN of the pancreas. World J Gastroenterol 2010;16:1890-1895.
[PubMed]
61.
Kanno A, Satoh K, Hirota M, Hamada S, Umino J, Itoh H, Masamune A, Asakura T, Shimosegawa T: Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas. J Gastroenterol 2010;45:952-959.
[PubMed]
62.
Maguchi H, Tanno S, Mizuno N, Hanada K, Kobayashi G, Hatori T, Sadakari Y, Yamaguchi T, Tobita K, Doi R, Yanagisawa A, Tanaka M: Natural history of branch duct intraductal papillary mucinous neoplasms of the pancreas: a multicenter study in Japan. Pancreas 2011;40:364-370.
[PubMed]
63.
Tanaka M: Controversies in the management of pancreatic IPMN. Nat Rev Gastroenterol Hepatol 2011;8:56-60.
[PubMed]
64.
Kobayashi G, Fujita N, Maguchi H, Tanno S, Mizuno N, Hanada K, Hatori T, Sadakari Y, Yamaguchi T, Tobita K, Doi R, Yanagisawa A, Tanaka M; Working Group for the Natural History of IPMN of the Japan Pancreas Society: Natural history of branch duct intraductal papillary mucinous neoplasm with mural nodules: a Japan Pancreas Society multicenter study. Pancreas 2014;43:532-538.
[PubMed]
65.
Tamura K, Ohtsuka T, Ideno N, Aso T, Kono H, Nagayoshi Y, Shindo K, Ushijima Y, Ueda J, Takahata S, Ito T, Oda Y, Mizumoto K, Tanaka M: Unresectable pancreatic ductal adenocarcinoma in the remnant pancreas diagnosed during every-6-month surveillance after resection of branch duct intraductal papillary mucinous neoplasm: a case report. JOP 2013;14:450-453.
[PubMed]
66.
Kamata K, Kitano M, Kudo M, Sakamoto H, Kadosaka K, Miyata T, Imai H, Maekawa K, Chikugo T, Kumano M, Hyodo T, Murakami T, Chiba Y, Takeyama Y: Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms. Endoscopy 2014;46:22-29.
[PubMed]
67.
Ideno N, Ohtsuka T, Kono H, Fujiwara K, Oda Y, Aishima S, Ito T, Ishigami K, Tokunaga S, Ohuchida K, Takahata S, Nakamura M, Mizumoto K, Tanaka M: Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. Ann Surg 2013;258:141-151.
[PubMed]
68.
Ohtsuka T, Kono H, Tanabe R, Nagayoshi Y, Mori Y, Sadakari Y, Takahata S, Oda Y, Aishima S, Igarashi H, Ito T, Ishigami K, Nakamura M, Mizumoto K, Tanaka M: Follow-up study after resection of intraductal papillary mucinous neoplasm of the pancreas; special references to the multifocal lesions and development of ductal carcinoma in the remnant pancreas. Am J Surg 2012;204:44-48.
[PubMed]
69.
Ohtsuka T, Ideno N, Aso T, Nagayoshi Y, Kono H, Mori Y, Takahata S, Oda Y, Aishima S, Igarashi H, Ito T, Ishigami K, Nakamura M, Mizumoto K, Tanaka M: Role of endoscopic retrograde pancreatography for early detection of pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm of the pancreas. J Hepatobiliary Pancreat Sci 2013;20:356-361.
[PubMed]
70.
Mori Y, Ohtsuka T, Tamura K, Ideno N, Aso T, Kono H, Nagayoshi Y, Ueda J, Takahata S, Aishima S, Ookubo F, Oda Y, Tanaka M: Intraoperative irrigation cytology of the remnant pancreas to detect remnant distinct pancreatic ductal adenocarcinoma in patients with intraductal papillary mucinous neoplasm undergoing partial pancreatectomy. Surgery 2014;155:67-73.
[PubMed]
71.
Iglesias-Garcia J, Lariño-Noia J, Dominguez-Muñoz JE: Early diagnosis of pancreatic cancer, time to screen high-risk individuals? Minerva Gastroenterol Dietol 2011;57:205-212.
[PubMed]
72.
Bartsch DK, Dietzel K, Bargello M, Matthaei E, Kloeppel G, Esposito I, Heverhagen JT, Gress TM, Slater EP, Langer P: Multiple small ‘imaging' branch-duct type intraductal papillary mucinous neoplasms (IPMNs) in familial pancreatic cancer: indicator for concomitant high grade pancreatic intraepithelial neoplasia? Fam Cancer 2013;12:89-96.
[PubMed]
73.
Shi C, Klein AP, Goggins M, Maitra A, Canto M, Ali S, Schulick R, Palmisano E, Hruban RH: Increased prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 2009;15:7737-7743.
[PubMed]
74.
Poley JW, Kluijt I, Gouma DJ, Harinck F, Wagner A, Aalfs C, van Eijck CH, Cats A, Kuipers EJ, Nio Y, Fockens P, Bruno MJ: The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 2009;104:2175-2181.
[PubMed]
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.
